Kala Pharmaceuticals to Present at the 2018 American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) and at the Ophthalmology Innovation Summit at ASCRS
Details of the presentations are as follows:
Meeting: OIS@ASCRS
Session title: Spotlight on Dry Eye
Date:
Time:
Location: The
Renaissance
Presenter:
Meeting: ASCRS
Title: Safety and Efficacy of
Date:
Time:
Location:
Presenter:
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the development and
commercialization of therapeutics using its proprietary
mucus-penetrating particle (MPP) technology, with an initial focus on
the treatment of eye diseases. Kala has applied the MPP technology to a
corticosteroid designed for ocular applications, resulting in two lead
product candidates. The product candidates are INVELTYS™ (KPI-121 1%)
for the treatment of inflammation and pain following ocular surgery, for
which an NDA has been accepted for review by the
View source version on businesswire.com: https://www.businesswire.com/news/home/20180409005434/en/
Source:
Investors and Media:
MacDougall Biomedical Communications
Cammy
Duong, 781-591-3443
cduong@macbiocom.com